KORU Medical Systems Inc

The stock remains in a Stage 4 decline with lower highs and lower lows, and medium-term directional asymmetry favors the downside. A recent momentum breakout has been met with resistance at declining EMAs and the 50DMA, suggesting exhaustion rather than reversal. Execution favors trimming positions into the current rally into the overhead resistance zone around the falling EMAs and 50DMA.

• ↑Q1 2026 revenue reached $11.8M, up 22% YoY
• ↑International revenues grew 35% YoY via European syringe conversions
• ↓Negative earnings yield and book-to-price ratio signal valuation risk